Thierry André, MD, of Hôpital Saint-Antoine, and Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discuss findings from their respective CheckMate-142 studies on nivolumab and ipilimumab in patients with DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer (Abstracts 553, 554).
Basem Azab, MD, of the Sylvester Comprehensive Cancer Center, University of Miami, discusses the impact on overall survival when more than 2 months elapse between finishing neoadju...
Steven D. Leach, MD, of Dartmouth University’s Norris Cotton Cancer Center, discusses the personalized approach that GI cancers will require to make rational use of immunotherapy—i...
David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the merits of preoperative chemotherapy vs chemoradiotherapy, the role of targeted agents, recent resu...
Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses study findings on pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sora...
Florian Lordick, MD, of the University Medicine Leipzig, discusses study findings on intraperitoneal immunotherapy with the antibody catumaxomab for patients with peritoneal carcin...